Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
BERKELEY, Calif., May 15, 2017 -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the Company’s new strategic initiatives and value drivers at the UBS Global Healthcare Conference on Monday, May 22, 2017, at 8:30 a.m. ET. The conference is being held at the Grand Hyatt New York hotel.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 90 days following the presentation.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 [email protected] Media contact: Colin Sanford Pure Communications +1 415-946-1094 [email protected]
